Apellis Pharmaceuticals (NASDAQ:APLS) Given “Outperform” Rating at Robert W. Baird

Robert W. Baird restated their outperform rating on shares of Apellis Pharmaceuticals (NASDAQ:APLS) in a research report sent to investors on Tuesday, Benzinga reports. They currently have a $100.00 price objective on the stock.

Several other equities research analysts also recently commented on APLS. Mizuho decreased their price objective on Apellis Pharmaceuticals from $60.00 to $52.00 and set a neutral rating for the company in a report on Monday, April 29th. UBS Group decreased their price objective on Apellis Pharmaceuticals from $89.00 to $85.00 and set a buy rating for the company in a report on Wednesday, May 8th. Piper Sandler assumed coverage on Apellis Pharmaceuticals in a report on Friday, May 31st. They set a neutral rating and a $46.00 price objective for the company. Wedbush decreased their price target on Apellis Pharmaceuticals from $67.00 to $57.00 and set a neutral rating for the company in a report on Wednesday, April 17th. Finally, Wells Fargo & Company decreased their price target on Apellis Pharmaceuticals from $57.00 to $48.00 and set an equal weight rating for the company in a report on Thursday, May 23rd. Four analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of Moderate Buy and a consensus price target of $74.75.

Apellis Pharmaceuticals Trading Up 4.0 %

Shares of APLS stock opened at $38.88 on Tuesday. The company has a market cap of $4.72 billion, a P/E ratio of -11.24 and a beta of 0.88. The stock has a 50 day simple moving average of $39.67 and a two-hundred day simple moving average of $52.13. The company has a debt-to-equity ratio of 0.35, a quick ratio of 3.02 and a current ratio of 3.77. Apellis Pharmaceuticals has a fifty-two week low of $19.83 and a fifty-two week high of $73.80.

Apellis Pharmaceuticals (NASDAQ:APLS) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.54) EPS for the quarter, meeting the consensus estimate of ($0.54). The firm had revenue of $172.33 million during the quarter, compared to the consensus estimate of $163.37 million. Apellis Pharmaceuticals had a negative return on equity of 160.77% and a negative net margin of 79.67%. The company’s quarterly revenue was up 284.3% on a year-over-year basis. During the same quarter in the previous year, the company posted ($1.56) earnings per share. Research analysts forecast that Apellis Pharmaceuticals will post -1.07 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Pascal Deschatelets sold 78,907 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $47,261,880.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, insider Pascal Deschatelets sold 78,907 shares of the company’s stock in a transaction on Wednesday, May 8th. The stock was sold at an average price of $42.35, for a total transaction of $3,341,711.45. Following the transaction, the insider now owns 1,115,983 shares of the company’s stock, valued at approximately $47,261,880.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director A. Sinclair Dunlop sold 37,000 shares of the company’s stock in a transaction on Friday, June 21st. The shares were sold at an average price of $39.24, for a total value of $1,451,880.00. Following the transaction, the director now directly owns 136,998 shares in the company, valued at approximately $5,375,801.52. The disclosure for this sale can be found here. Insiders own 6.80% of the company’s stock.

Institutional Trading of Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Future Financial Wealth Managment LLC bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at $29,000. BI Asset Management Fondsmaeglerselskab A S bought a new stake in shares of Apellis Pharmaceuticals during the 1st quarter valued at $89,000. CWA Asset Management Group LLC bought a new stake in shares of Apellis Pharmaceuticals during the 4th quarter valued at $205,000. Woodward Diversified Capital LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter worth about $210,000. Finally, HC Advisors LLC bought a new position in Apellis Pharmaceuticals in the 4th quarter worth about $210,000. 96.29% of the stock is currently owned by institutional investors.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).